Technology

May 31, 2015.

June 1, 2015.

The World Medical Innovation Forum unveils its inaugural list of breakthrough neuroscience technologies. We highlight a few here.

May 29, 2015.

May 29, 2015.

Prescription drug usage data on more than one million Marketplace enrollees suggest that costs for specialty drugs were 36% higher for people with Obamacare.

Boehringer Ingelheim announces FDA approval of Stiolto Respimat inhaler for the treatment of COPD.

MIT scientist Robert Langer will speak at BIO 2015 on a panel about venture capitalism in biotechnology.

Compliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.

May 26, 2015.

Medicines considered critically important for patients to remain available.

The former New England Compounding Center will pay $200 million to victims and creditors for the 2012 outbreak of meningitis that killed 64.

Physician confidence in biosimilars and extrapolation of indications are two of the most important factors governing the acceptance and sustainability of biosimilars, say industry panelists.

The House Energy and Commerce Committee gave unanimous approval to the landmark 21st Century Cures Act reform bill on May 21, 2015.

May 20, 2015.

Pharm Exec talks to Matt Wallach, President of Veeva Systems, an upstart start-up whose mix of cutting-edge technology and strong customer orientation has brought it to the top rank in providing cloud-based data management services to the industry.

May 20, 2015.

Alexion will construct a biologics facility in Ireland that is its first outside the US.

The company picked up the Pharm Exec Brand of the Year award last week at the iPharma event in New York.

May 19, 2015.

Raplixa fibrin sealant, the first approved spray-dried biologic, is a hemostatic agent that helps control bleeding from small blood vessels during surgery.

May 18, 2015.

AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

Juno Therapeutics announces that it will expand its cellular therapies pipeline with the acquisition of Stage Cell Therapeutics for €52.5 million.

Eli Lilly announces that it will establish a drug delivery and device center in Cambridge, Massachusetts.

Loreen M. Brown discusses how technology has influenced how healthcare teams function, from leveraging and delivering care to interacting with patients throughout the patient journey.

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.

May 13, 2015.

May 11, 2015.